Sorry, you need to enable JavaScript to visit this website.
Skip to main content
Last Updated
In the Matter of Glaxo Wellcome plc, and SmithKline Beecham plc
FTC Matter/File Number
0010088
Docket Number
C-3990
Enforcement Type
Part 2 Consents

Case Summary

Under terms of a final consent order settling charges stemming from the merger of SmithKline and Glaxo Wellcome plc, the parties agreed to divest pharmaceutical products in six markets: antiemetics; the antibiotic, ceftazidime; oral and intravenous antiviral drugs for the treatment of herpes; topical antiviral drugs for the treatment of genital herpes; and over-the-counter H-2 blocker acid relief products.